Immunic
IMUX
62 hedge funds and large institutions have $95M invested in Immunic in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 16 closing their positions.
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
17% more capital invested
Capital invested by funds: $81.3M → $95M (+$13.7M)
7% more funds holding
Funds holding: 58 → 62 (+4)
0.01% more ownership
Funds ownership: 0.07% → 0.08% (+0.01%)
77% less call options, than puts
Call options by funds: $754K | Put options by funds: $3.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.44M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$6.33M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.93M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.47M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$917K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.7M |
| 2 |
Millennium Management
New York
|
-$2.33M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.12M |
| 4 |
Goldman Sachs
New York
|
-$936K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$416K |
IMUX Hedge Fund Activity: Q2 2018 in Review
62 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q2 2018, worth a combined $95M — up 17% from $81.3M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new IMUX positions and 16 closed out — a net gain of 4 holders — while 20 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $7.44M. The largest seller was Fidelity Investments, cutting an estimated $6.7M.
- 62 institutional investors held Immunic (IMUX) as of Q2 2018, up from 58 in Q1 2018.
- Funds reported $95M of Immunic stock for Q2 2018, up 17% quarter-over-quarter.
- 20 funds opened new Immunic positions in Q2 2018 and 16 closed out, a net change of +4 holders.
- The largest Immunic buyer in Q2 2018 was BlackRock, an estimated $7.44M added.
- The largest Immunic seller in Q2 2018 was Fidelity Investments, an estimated $6.7M sold.
Based on aggregated 13F filings for Q2 2018.